Evotec SE (EVO) said Tuesday that it has advanced its neuroscience collaboration with Bristol Myers Squibb (BMY) by securing a research payment of $20 million for further development of a pre-clinical program in neurodegeneration.
The two companies started their collaboration in December 2016 to develop transformative treatments that can slow or halt disease progression for a broad range of neurodegenerative diseases.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。